Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 23/01/2024.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques fabriquées localement :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | DIFLUZOLE | Fluconazole | 100 | Gelule | B/7 | DAR ESSAYDALI | E | N | 20/12/2023 |
2 | DIFLUZOLE | Fluconazole | 200 | Gelule | B/7 | DAR ESSAYDALI | E | N | 20/12/2023 |
3 | LEVOREC | LEVOFLOXACINE | 750 mg | Comprimé pelliculé | B/10 | OPALIA PHARMA | E | N | 11/01/2024 |
4 | LEVOREC | LEVOFLOXACINE | 750 mg | Comprimé pelliculé | B/5 | OPALIA PHARMA | E | N | 11/01/2024 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | SACUVAL 100 | sacubitril+valsartan | 48.6mg/51.4mg | Comprimé pelliculé | B/30 | PHILADELPHIA PHARMA | E | N | 29/11/2023 |
2 | SACUVAL 200 | sacubitril+valsartan | 97.2mg/102.8mg | Comprimé pelliculé | B/30 | PHILADELPHIA PHARMA | E | N | 29/11/2023 |
3 | NOVAMOX | AMOXICILLINE | 1 gr | Comprime dispersible | B/21 | ADWYA | E | N | 14/12/2023 |
4 | NOVACLAV | AMOXICILLINE+ACIDE CLAVULANIQUE | 500 mg/62.5mg | Comprimé pelliculé | B/42 | ADWYA | E | N | 14/12/2023 |
5 | CYSTODOSE | FOSFOMYCINE | 3 g | Granulés pour solution buvable | B/4 sachets | SAIPH | E | N | 14/12/2023 |
6 | LIDOCA PLUS | LIDOCAINE+PRILOCAINE | 5% | Creme dermique | T/5 g | SIMED | E | N | 03/01/2024 |
7 | AMOXIL | AMOXICILLINE | 0.5 gr | Pdre p.prep.injectable | B/25 FL | UNIMED | E | N | 11/01/2024 |
8 | AMOXIL IM IV | AMOXICILLINE | 0.5 gr | Pdre p.prep.injectable | B/1flacon +solvant/5ml | UNIMED | E | N | 11/01/2024 |
9 | AMOXIL | AMOXICILLINE | 0.5 GR | Pdre p.prep.injectable | B/1FL/+S/5ml | UNIMED | E | V | 11/01/2024 |
10 | AMOXIL | AMOXICILLINE | 1 GR | Pdre p.prep.injectable | B/1FL/+S/5ml | UNIMED | E | V | 11/01/2024 |
11 | CEFTAZIM IV | CEFTAZIDIME | 2 gr | Pdre p.prep.injectable | B/1FL/ 20 ML+ set de transfert | UNIMED | E | V | 11/01/2024 |
12 | CEFTAZIM IM IV | CEFTAZIDIME | 1 gr | Pdre p.prep.injectable | B/1 fl s/solvant | UNIMED | E | V | 11/01/2024 |
13 | CEFTAZIM IM IV | CEFTAZIDIME | 0,5 gr | Pdre p.prep.injectable | B/1 fl s/solvant | UNIMED | E | V | 11/01/2024 |
14 | CIFLOXET 200 | CIPROFLOXACINE | 200 mg/100ml | Solution injectable | FL/100 ml | DORCAS | E | V | 11/01/2024 |
15 | CIFLOXET 200 | CIPROFLOXACINE | 200 mg/100ml | Solution injectable | B/6 flacons/100 ml | DORCAS | E | V | 11/01/2024 |
16 | CIPROJECT | CIPROFLOXACINE | 400 mg/200ml | Solution injectable pour perfu | poche/200 ml | UNIMED | E | V | 11/01/2024 |
17 | CIPROJECT | CIPROFLOXACINE | 200 mg//100ml | Solution injectable pour perfu | poche/100 ml | UNIMED | E | V | 11/01/2024 |
18 | CIPROJECT | CIPROFLOXACINE | 200 mg//100ml | Solution injectable pour perfu | poche multicouche/100 ml | UNIMED | E | V | 11/01/2024 |
19 | SIFLOKS | CIPROFLOXACINE | 500 MG | Comprimé pelliculé sécable | B/28 | TERIAK | E | V | 11/01/2024 |
20 | SIFLOKS | CIPROFLOXACINE | 500 MG | Comprimé pelliculé sécable | B/14 | TERIAK | E | V | 11/01/2024 |
21 | SIFLOKS | CIPROFLOXACINE | 750 MG | Comprimé pelliculé sécable | B/14 | TERIAK | E | V | 11/01/2024 |
22 | SIFLOKS | CIPROFLOXACINE | 750 MG | Comprimé pelliculé sécable | B/28 | TERIAK | E | V | 11/01/2024 |
23 | CIPROSAIPH | CIPROFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/14 | SAIPH | E | V | 11/01/2024 |
24 | TAVACET 500 | LEVOFLOXACINE | 5 MG/ML | Solution injectable pour perfu | FL/100 ML | DORCAS | E | V | 11/01/2024 |
25 | TAVACET 500 | LEVOFLOXACINE | 5 mg/ml | Solution injectable pour perfu | B/ 6 flacons/ 100 ml | DORCAS | E | V | 11/01/2024 |
26 | TAVANIC | LEVOFLOXACINE | 500 MG | Comprimé pelliculé | B/5 | SANOFI AVENTIS PHARMA TUNISIE | E | V | 11/01/2024 |
27 | TAVANIC | LEVOFLOXACINE | 500 MG | Comprimé pelliculé | B/10 | SANOFI AVENTIS PHARMA TUNISIE | E | V | 11/01/2024 |
28 | TAVAFLOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | TERIAK | E | V | 11/01/2024 |
29 | TAVAFLOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | TERIAK | E | V | 11/01/2024 |
30 | LEVOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | ADWYA | E | V | 11/01/2024 |
31 | LEVOX | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | ADWYA | E | V | 11/01/2024 |
32 | LOVIK | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/10 | PHILADELPHIA PHARMA | E | V | 11/01/2024 |
33 | LOVIK | LEVOFLOXACINE | 500 mg | Comprimé pelliculé sécable | B/5 | PHILADELPHIA PHARMA | E | V | 11/01/2024 |
Spécialités Pharmaceutiques importées
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | CRESEMBA | ISAVUCONAZOLE | 100 MG | GEL | B/14 | HIKMA Pharmaceuticals | N | 11/07/2023 | |
2 | ERLEADA | APALUTAMIDE | 60 mg | COMP PEL | B/112 | Janssen-Cilag International N.V | N | 14/11/2023 | |
3 | OPSUMIT | MACITENTAN | 10 mg | COMP PEL | B/30 | Janssen-Cilag International N.V | N | 20/11/2023 | |
4 | UPTRAVI | SELEXIPAG | 200 mcg | COMP PEL | B/140 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
5 | UPTRAVI | SELEXIPAG | 200 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
6 | UPTRAVI | SELEXIPAG | 400 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
7 | UPTRAVI | SELEXIPAG | 600 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
8 | UPTRAVI | SELEXIPAG | 800 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
9 | UPTRAVI | SELEXIPAG | 1000 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
10 | UPTRAVI | SELEXIPAG | 1200 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
11 | UPTRAVI | SELEXIPAG | 1400 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
12 | UPTRAVI | SELEXIPAG | 1600 mcg | COMP PEL | B/60 | Janssen-Cilag International N.V | V | N | 20/11/2023 |
13 | Skyrizi | Risankizumab | 150 Mg | Sol Inj | B/1 Stylo Pré-Remplie | Abbvie Deutschland Gmbh And Co.Kg | N | ||
14 | Skyrizi | Risankizumab | 151 Mg | Sol Inj | B/1 Stylo Pré-Remplie | Abbvie Deutschland Gmbh And Co.Kg | N | ||
15 | ENSPRYNG | SATRALIZUMAB | 120 mg/1 ml | SOL INJ | B/1 seringue pré-remplie de 1ml | Roche Pharma (Schweiz) AG | N | 22/11/2023 | |
16 | KALINOR - retard P | CHLORURE DE POTASSIUM | 600 mg | GEL | B/50 | DESMA GmbH | N | 22/11/2023 | |
17 | POVIDEX | POVIDONE IODEE | 5% | SUPPO VAGINAL | B/12 | BEIT JALA Pharmaceutical Co | I | N | 12/06/2023 |
18 | MYCOTEN | CLOTRIMAZOLE | 200 mg | COMP GYN | B/3 avec applicateurs | BEIT JALA Pharmaceutical Co | I | N | 12/11/2023 |
19 | MYCOTEN VAGINAL CREAM | CLOTRIMAZOLE | 2% | CREM VAGINAL | T/20g | BEIT JALA Pharmaceutical Co | I | N | 12/11/2023 |
20 | MYCOTEN | CLOTRIMAZOLE | 500 mg | COMP GYN | B/1 Comprimé + Applicateur | BEIT JALA Pharmaceutical Co | I | N | 12/11/2023 |
21 | EVRYSDI | RISDIPLAM | 0.75 mg/ml | PDRE PR SOL ORAL | FL/100 ml | Roche Pharma (Schweiz) AG | N | 11/12/2023 | |
22 | KADCYLA | TRASTUZUMAB | 160 MG | PDRE PR SOL SOL PR PF | B/1FL /20ml (160mg de poudre) | ROCHE PHARMA (SCHWEIZ) LTD SUISSE | N | 11/12/2023 | |
23 | KADCYLA | TRASTUZUMAB | 100 MG | PDRE PR SOL SOL PR PF | B/1FL /20ml (160mg de poudre) | ROCHE PHARMA (SCHWEIZ) LTD SUISSE | N | 11/12/2023 | |
24 | KISQALI | RIBICICLIB | 200 mg | COMP PEL | B/63 | NOVARTIS PHARMA | V | 14/12/2023 | |
25 | RILUZOL PMCS | RILUZOLE | 50 MG | COMP PEL | B/56 | PRO.MED.CS Praha a.s | N | 20/12/2023 | |
26 | ATOSIBAN EVER Pharma | ATOSIBAN | 37.5 mg/ 5 ml | SOL INJ PR PRF | B/1 flacon / 5ml | EVER Valinject GmbH | E | N | 22/12/2023 |
27 | ATOSIBAN EVER Pharma | ATOSIBAN | 75 mg/ 10 ml | SOL INJ PR PRF | B/1 flacon / 10ml | EVER Valinject GmbH | E | N | 22/12/2023 |
28 | ATOSIBAN EVER Pharma | ATOSIBAN | 6,75 mg/ 0,9 ml | SOL INJ PR PRF | B/1 flacon / 2 ml | EVER Valinject GmbH | E | N | 22/12/2023 |
29 | NASONEX | MOMETASONE | 50 MCG/DOSE | Susp NASAL | FL/140 DOSES | ORGANON TECHNIKA FRANCE | E | T | 04/01/2024 |
30 | Pemzek | Candesartan | 8 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | 11/01/2024 |
31 | Pemzek | Candesartan | 16 mg | comprimé | B/28 | ASTRA ZENECA SUISSE | E | T | 11/01/2024 |
* Produits à évaluer pour la première fois au Comité Technique
Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE | |
1 | SEMGLEE | INSULINE GLARGINE | 100 UI/ml | SOL INJ | B/5 stylos pré-remplis | Biosimilar Collaborations Ireland Limited ("BCIl") | V | T | 17/10/2023 |
2 | MYCOSTER VERNIS | CICLOPIROXOLAMINE | 8% | SOL EXTERNE | FL/3ML | PIERRE FABRE MEDICAMENT . | E | T | 26/10/2023 |
3 | MYCOSTER | CICLOPIROXOLAMINE | 1% | PDRE A USAGE EXTERNE | FL/30 GR | PIERRE FABRE MEDICAMENT . | E | T | 26/10/2023 |
4 | ABSTRAL | FENTANYL | 100 µg | COMP SUBL | B/10 | KYOWA KIRIN INC | V | N | 11/03/2023 |
5 | ABSTRAL | FENTANYL | 200 µg | COMP SUBL | B/10 | KYOWA KIRIN INC | V | N | 11/03/2023 |
6 | DIPROSTENE | BETAMETHASONE | 7 MG | SUSP INJ | B/1SER | Organon France | E | T | 11/07/2023 |
7 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/2seringues prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
8 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/2 Stylos prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
9 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/1seringues préremplies | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
10 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/4 Stylos préremplis | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
11 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/4 seringues préremplies | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
12 | REMSIMA SC | INFLIXIMAB | 120 mg | SOL INJ | B/1 stylo prérempli | HIKMA Pharmaceuticals | E | N | 11/08/2023 |
13 | AERIUS | DESLORATADINE | 5 mg | Cp Pell | B/15 | NV ORGANON PAY BAS | E | T | 05/12/25023 |
14 | ZINNAT | CEFUROXIME | 500 mg | Cp Pell | B/10 | SANDOZ PHARMACEUTICALS DD SLOVENIE | 11/12/2023 | ||
15 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+OLMESARTAN MEDOXOMIL | 40 mg/5mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
16 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+ OLMESARTAN MEDOXOMIL | 20 mg/5mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
17 | OLMESATAN MEDOXOMIL & AMLODIPINE /GENEPHARM | AMLODIPINE+ OLMESARTAN MEDOXOMIL | 40 mg/10mg | COMP PEL | B/30 | GENEPHARM S.A | E | N | 12/12/2023 |
18 | CARDENSIEL | BISOPROLOL | 1.25 mg | COMP PEL | B/30 | Merck Santé s.a.s | E | N | 12/12/2023 |
19 | DIBASE | CHOLÉCALCIFÉROL | 50 000 UI /2.5ML | SOL BUV | B/ 1FL | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
20 | DIBASE | CHOLÉCALCIFÉROL | 100 000 UI /ML | SOL INJ | B/6 ampoules de 1ml | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
21 | DIBASE | CHOLÉCALCIFÉROL | 25 000 UI /2.5ML | SOL BUV | B/ 1FL monodose de 2.5 ml | ABIOGEN PHARMA S.p.A | E | N | 13/12/2023 |
22 | DIVINUSMET XR | DAPAGLIFLOZINE PROPANEDIOL / METFORMINE CHLORHYDRATE | 10 mg/1000 mg | COMP PEL | B/30 | HIKMA Pharmaceuticals | N | 13/12/2023 | |
23 | DIVINUSMET XR | DAPAGLIFLOZINE PROPANEDIOL / METFORMINE CHLORHYDRATE | 5 mg/1000 mg | COMP PEL | B/60 | HIKMA Pharmaceuticals | N | 13/12/2023 | |
24 | TOUJEO SOLOSTAR | INSULINE GLARGINE | 300 UI/ML | SOL INJ | B/3 STYLOS | SANOFI AVENTIS DEUTSCHLAND GmbH | V | V | CS 13/12/2023 |
25 | JANUMET | SITAGLIPTINE+METFORMINE | 50 mg/850mg | COMP PEL | B/56 | MERCK SHARP & DOHME BV | E | T | 13/12/2023 |
26 | SULIQUA | INSULINE GLARGINE + LIXISENATIDE | 100 Unités/ml + 50 µg/ml | SOL INJ | B/3 Stylos | SANOFI-AVENTIS FRANCE | V | N | 13/12/2023 |
27 | SULIQUA | INSULINE GLARGINE + LIXISENATIDE | 100 Unités /ml + 33 µg/ml | SOL INJ | B/3 Stylos | SANOFI-AVENTIS FRANCE | V | N | 13/12/2023 |
28 | BAXDELA | DELAFLOXACINE MEGLUMINE | 450 mg | COMP | B/20 | HIKMA Pharmaceuticals | N | CS 14/12/2023 | |
29 | BAXDELA | DELAFLOXACINE MEGLUMINE | 300 mg | PDRE PR PREP INJ | B/10FL/20ML | HIKMA Pharmaceuticals | N | CS 14/12/2023 | |
30 | MONURIL ADULTE | FOSFOMYCINE | 3 G | GRANULE PR SUSP BUV | B/1SACHET | ZAMBON FRANCE | E | V | CS 14/12/2023 |
31 | HEXAXIM | VACCIN D+T+C+P+HB+HIB | SUSP INJ | B/1 SER | SANOFI PASTEUR SA | E | V | CS 11/01/2024 |